----- Original Message -----
Sent: Saturday, September 29, 2001 11:47
AM
Subject: Re: Re: [sharechat] Genesis (
NZSE.GEN ) or Peptech ( AX. PTD )
Readers, before proceeding, please read the
Disclaimer in my previous post!
Thank you, Colin!
I always appreciate a comment from a
pharmacist!
There is a large market for anti-TNF
pharmaceuticals now.
Below are comments from "
Decision Resources, Inc."
which reviews the commercial potential of novel agents in this
field:
The TNF-Alpha Inhibitors in therapeutic products: " Etanercept "(
Immmunex/Wyeth-Ayerst's Enbrel ), " Infliximab " (
Centocor/ Johnson@ Johnson's Remicade ) being used in
the rheumatoid arthritis ( RA ) and inflammatory bowel disease(
IBD).
They predict that by 2010 approx. 37%
of the anti-TNF market place will be attributed to sales in novel
indications.
Psoriasis and
Psoriatic Arthritis trials are now in
late-stage clinical development and the TNF inhibitor will be the
principal driver of growth in this market according to
forecasts.
Congestive
Heart Failure ( CHF) This seems to be
associated with high levels of TNF bio activity. This requires further
study.
Sepsis: A modest but definite
beneficial effect by application of a refined anti- TNF product "
Afelimomab " ( Knoll/Abbott's Segard ) in an improved clinical trial design,
have been noted.
Yes, I have followed the TNF- Alpha
Inhibitor market closely; it is showing great promise and profits
are rising exponentially: It is a massive market!
This post and the previous one were mainly
written for this site:
This is the prime Australian Message Board on
PTD.
I promised to do a summary of the status of
PTD: See post 3241on that site.
( See also posts 340 and 1069 from the
MMD Message Board).
There are some principal contributors there and
they are nice people to work with: these traders are a team and act
accordingly.
Gerry